Latest news with #PRCT
Business Insider
15-07-2025
- Business
- Business Insider
Procept BioRobotics says Aquablation therapy assigned a Category I code
The company states: 'PROCEPT BioRobotics (PRCT) announced that Aquablation therapy was assigned a Category I code effective January 1, 2026. The 2026 Medicare Proposed Physician Fee Schedule includes payment rates for a new Category I Current Procedural Terminology code related to Aquablation therapy. Category I CPT code 52XX1 will replace Category III CPT code 0421T as the primary code for Aquablation therapy. The new CPT Category I Code 52XX1 was assigned a 2026 national Medicare physician proposed payment of 16.14 total RVUs which translates to an approximate national average of $540, under the 2026 proposed Medicare PFS. By comparison, TURP was assigned 15.82 total RVUs which translate to an approximate national average of $529.' Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Business Insider
06-06-2025
- Business
- Business Insider
PROCEPT BioRobotics (PRCT) Gets a Buy from TD Cowen
In a report released yesterday, Josh Jennings from TD Cowen reiterated a Buy rating on PROCEPT BioRobotics (PRCT – Research Report). The company's shares closed yesterday at $65.05. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Jennings covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Medtronic, and Establishment Labs Holdings. According to TipRanks, Jennings has an average return of 4.6% and a 52.11% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for PROCEPT BioRobotics with a $80.20 average price target. PRCT market cap is currently $3.32B and has a P/E ratio of -36.24. Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PRCT in relation to earlier this year. Most recently, in March 2025, Reza Zadno, the President & CEO of PRCT sold 5,475.00 shares for a total of $312,403.50.
